As part of the Diopsys^® University™ E-Learning Webinar series,  Dr. Alberto Gonzalez  will discuss in depth the Diopsys^®mfERGVision Test and report interpretation. As eye care specialists, you frequently co-manage patients with other health care providers such as primary care physicians, rheumatologists, and neurologists. This often makes you the first line of detection when certain medications prescribed by those physicians start negatively impacting the patient’s retina. In some cases, retinal dysfunction may occur without structural abnormalities, requiring a robust functional testing method to detect retinal toxicity early.^1-3 Diopsys^® mfERG (multifocal electroretinography) vision tests provide you with the objective, functional information you need to help recognize the first signs of drug-induced retinopathy, and work with the other providers to make the best clinical decisions for each patient.

1.Dettoraki M, Moschos MM. The Role of Multifocal Electroretinography in the Assessment of Drug-Induced Retinopathy: A Review of the Literature. Ophthalmic Res 2016;56:169–177 2.Talamini CL, et al. Abnormal multifocal ERG findings in patients with normal-appearing retinal anatomy. Doc Ophthalmol 2011;123(3):187-192. 3.Marmor, M, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016;123:6:1386-1394 4.Hood, DC, et al. ISCEV Standard for clinical multifocal electroretinography (2011 edition). Doc Ophthalmol 124:1–13.